01 7Regpara
02 1Sensipar
03 1Sensipar /Mimpara
04 6Sensipar/ Mimpara
05 1Sensipar/Mimpara
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2020 Revenue in Millions : 288
2019 Revenue in Millions : 551
Growth (%) : -48
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2020 Revenue in Millions : 115
2019 Revenue in Millions : 109
Growth (%) : 5
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2021 Revenue in Millions : 84
2020 Revenue in Millions : 288
Growth (%) : -71
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2021 Revenue in Millions : 87
2020 Revenue in Millions : 115
Growth (%) : -15
Main Therapeutic Indication : Endocrinology
Currency : USD
2022 Revenue in Millions : 64
2021 Revenue in Millions : 84
Growth (%) : -24
Main Therapeutic Indication : Endocrinology
Currency : USD
2022 Revenue in Millions : 46
2021 Revenue in Millions : 87
Growth (%) : -47
Main Therapeutic Indication : Endocrinology
Currency : USD
2023 Revenue in Millions : 38
2022 Revenue in Millions : 46
Growth (%) : -7
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2015 Revenue in Millions : 1,158
2014 Revenue in Millions : 1,415
Growth (%) : 22%
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2017 Revenue in Millions : 1,718
2016 Revenue in Millions : 1,582
Growth (%) : 9
Main Therapeutic Indication : Hormonal Disorders
Currency : USD
2018 Revenue in Millions : 1,774
2017 Revenue in Millions : 1,718
Growth (%) : 3%
LOOKING FOR A SUPPLIER?